SCHEMBL3910693

SCHEMBL3910693

COC(=O)C(O)Cc1cc(Cl)c(Oc2ccc([N+](=O)[O-])cc2)c(Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
GAA P10253 3/20 0.42
PKM P14618 1/20 0.42
POLB P06746 3/20 0.41
MAPT P10636 3/20 0.41
THRA P10827 1/20 0.41
THRB P10828 1/20 0.41
NPSR1 Q6W5P4 3/20 0.40
MAPK1 P28482 2/20 0.40
RAB9A P51151 2/20 0.40
NPC1 O15118 1/20 0.40
MYOC Q99972 1/20 0.40
ALDH1A1 P00352 2/20 0.40
HTT P42858 2/20 0.40
PTPN7 P35236 1/20 0.40
PTPN12 Q05209 1/20 0.40
PTPN22 Q9Y2R2 1/20 0.40
LMNA P02545 1/20 0.40
ADRB2 P07550 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3911322 0.89 MEN1 (0.42) MEN1KMT2AGAAPKMPOLB
SCHEMBL3918789 0.86 KMT2A (0.40) MEN1KMT2AGAAPOLBMAPT
SCHEMBL3914044 0.81 THRA (0.50) MEN1KMT2AGAAPKMPOLB
SCHEMBL6823644 0.80 KMT2A (0.49) MEN1KMT2AGAAPOLBMAPT
SCHEMBL3913177 0.79 THRA (0.45) MEN1KMT2AGAAPKMPOLB
SCHEMBL14519762 0.77 THRB (0.68) MEN1KMT2ATHRATHRB
SCHEMBL3911699 0.75 KMT2A (0.40) MEN1KMT2AGAAPOLBMAPT
SCHEMBL5394385 0.74 MAPT (0.47) MEN1KMT2AGAAPKMPOLB
SCHEMBL3986085 0.73 HTT (0.53) MEN1KMT2AGAAPKMMAPT
SCHEMBL7121943 0.73 MEN1 (0.49) MEN1KMT2AGAAPKMPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090318514-A1 Novel Pharmaceutical Compositions KARO BIO AB (SE) 2009-12-24 US disclosed
EP-2024336-A1 NOVEL PHARMACEUTICAL COMPOSITIONS KARO BIO AB (SE) 2009-02-18 EP disclosed
WO-2007128492-A1 NOVEL PHARMACEUTICAL COMPOSITIONS KARO BIO AB (SE) 2007-11-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318514-A1 Novel Pharmaceutical Compositions TSHR, TRHR, THRA MEN1 775/4885KMT2A 2430/4885GAA 3977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.